Sunday, February 27, 2011

A North American first at the Montreal Heart Institute could help treat thousands of Canadians

The interventional cardiology team at the Montreal Heart Institute recently began patient enrolment for a new device, the Neovasc Reducer, designed to treat patients suffering from refractory angina. The treatment method is a first in North America and is being conducted as part of an international study, the COSIRA trial. This innovative treatment is promising for thousands of Canadians disabled by refractory angina and who lack alternatives for relieving their symptoms and improving their quality of life

No comments: